GlobeNewsWire
04 Jun 2026, 20:37 UTC · 4h ago
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
Search tags
GlobeNewsWire
04 Jun 2026, 20:37 UTC · 4h ago
Search tags
Story key points
2 claims · impact-rated
Tempest Therapeutics has developed a portfolio of CAR-T cell therapy product candidates for advanced cancers. — The shift or expansion into a specific high-growth therapeutic area like CAR-T indicates a strategic direction for the company's pipeline.
+0.30Tempest Therapeutics appointed Drake Richey and Dr. John Yee to its Board of Directors. — Adding experienced leadership in corporate finance and medical affairs is generally positive but rarely a primary catalyst for immediate price movement.
+0.10Ticker attribution
Model heads
The company appointed two experienced independent directors to its board to support growth and capital allocation.
Continue reading
6 related stories
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
0 dimensions · 9 clusters
No impact vector found for this article yet.
Market reaction
0 bid · 0 offered
No stock impact ranking available yet.
No stock impact ranking available yet.
PRNewsWire
3h ago
